Hepatitis C Treatment in People With HIV: Potential to Eliminate Disease and Disparity.
Hepatitis C Treatment in People With HIV: Potential to Eliminate Disease and Disparity.
复制标题
艾滋病毒感染者的丙型肝炎治疗：消除疾病和差异的潜力。
DOI：
10.1093/infdis/jiad433
复制
发表时间：
2024
期刊：
影响因子：
--
通讯作者：
Sulkowski,Mark
中科院分区：
文献类型：
--
作者：
Falade-Nwulia,Oluwaseun;Lesko,CatherineR;Fojo,AnthonyT;Keruly,JeanneC;Moore,RichardD;Sutcliffe,CatherineG;Mehta,ShrutiH;Chander,Geetanjali;Thomas,DavidL;Sulkowski,Mark
获得直接作用的抗病毒药物（DAA）可能与人类免疫缺陷病毒（PWH）感染者中丙型肝炎病毒（HCV）病毒血症患病率的降低有关。在3755名PWH中，估计的HCV病毒血症患病率从2009年（DAA前时代）的36%（95%置信区间[CI]，27%-46%）下降到2021年（DAA时代）的2%（95% CI，0%-4%），下降了94.0%。2009年，男性、黑人和老年人与HCV病毒血症相关，但2021年与此无关。2009年和2021年，注射毒品仍然与HCV病毒血症相关。需要有针对性的干预措施，以满足吸毒的PWH的HCV护理需求。
Access to direct acting antivirals (DAAs) may be associated with reductions in hepatitis C virus (HCV) viremia prevalence among people with human immunodeficiency virus (PWH). Among 3755 PWH, estimated HCV viremia prevalence decreased by 94.0% from 36% (95% confidence interval [CI], 27%–46%) in 2009 (pre-DAA era) to 2% (95% CI, 0%–4%) in 2021 (DAA era). Male sex, black race, and older age were associated with HCV viremia in 2009 but not in 2021. Injection drug use remained associated with HCV viremia in 2009 and 2021. Targeted interventions are needed to meet the HCV care needs of PWH who use drugs.